Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Rhabdomyolysis
Interventions
DRUG

N-Acetylcysteine

Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W

OTHER

N-Acetylcystine and Non CRRT

Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind

OTHER

Placebo and CRRT

Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label

OTHER

Placebo and Non CRRT

Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind

Trial Locations (2)

11426

King Fahad National Guard Hospital, Riyadh

T5H 3V9

Royal Alexandra Hospital, Edmonton

All Listed Sponsors
collaborator

University of Alberta

OTHER

collaborator

Gambro Renal Products, Inc.

INDUSTRY

lead

Royal Alexandra Hospital

OTHER

NCT00391911 - Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis | Biotech Hunter | Biotech Hunter